Multimodal treatment of hepatocellular carcinoma

European Journal of Internal Medicine

Volumn 25, Issue 5, 2014, Pages 430-437

  Graf, Dirk ^a   Vallböhmer, Daniel ^a   Knoefel, Wolfram Trudo ^a   Kröpil, Patric ^a   Antoch, Gerald ^a   Sagir, Abdurrahaman ^a   Häussinger, Dieter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Radiofrequency ablation; Sorafenib; Transarterial chemoembolization

Indexed keywords

PLACEBO; SORAFENIB;

ALTERNATING CURRENT; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ELECTROCORTICOGRAPHY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HYPERBILIRUBINEMIA; HYPERTHERMIC THERAPY; INJECTION; LASER INDUCED THERMOTHERAPY; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); MICROWAVE THERAPY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PERCUTANEOUS ETHANOL INJECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; REVIEW; SELECTIVE INTERNAL RADIATION THERAPY; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMIC THERAPY; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT FAILURE; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMPLICATION; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICROWAVE RADIATION; PATHOLOGY; PROGNOSIS;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; HUMANS; HYPERTHERMIA, INDUCED; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MICROWAVES; NEOPLASM STAGING; PROGNOSIS;

EID: 84901632287     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2014.03.001     Document Type: Review

References (105)

1. F.X. Bosch, J. Ribes, M. Diaz, and R. Cleries Primary liver cancer: worldwide incidence and trends Gastroenterology 127 2004 S5 S16
2. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
3. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
4. G. Fattovich, T. Stoffolini, I. Zagni, and F. Donato Hepatocellular carcinoma in cirrhosis: incidence and risk factors Gastroenterology 127 2004 S35 S50
5. J. Bruix, and M. Sherman Management of hepatocellular carcinoma. An update Hepatology 53 2011 1020 1022
6. J.M. Llovet, C. Bru, and J. Bruix Prognosis of hepatocellular carcinoma: the BCLC staging classification Semin Liver Dis 19 1999 329 338
7. F. Pons, M. Varela, and J.M. Llovet Staging systems in hepatocellular carcinoma HPB 7 2005 35 41
8. J.J. Goldberger, and A.E. Buxton Personalized medicine vs guideline-based medicine JAMA 309 2013 2559 2560
9. S. Roayaie, K. Obeidat, C. Sposito, L. Mariani, S. Bhoori, and A. Pellegrinelli et al. Resection of hepatocellular cancer ≤ 2 cm: results from two Western centers Hepatology 57 2013 1426 1435
10. T. Livraghi, F. Meloni, M. Di Stasi, E. Rolle, L. Solbiati, and C. Tinelli et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology 47 2008 82 89
11. K. Berry, and G.N. Ioannou Are patients with Child's A cirrhosis and hepatocellular carcinoma appropriate candidates for liver transplantation? Am J Transplant 12 2012 706 717
12. S. Arii, Y. Yamaoka, S. Futagawa, K. Inoue, K. Kobayashi, and M. Kojiro et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan Hepatology 32 2000 1224 1229
13. J.M. Llovet, and J. Bruix Novel advancements in the management of hepatocellular carcinoma in 2008 J Hepatol 48 2008 S20 S37
14. G. Cabibbo, M. Enea, M. Attanasio, J. Bruix, A. Craxi, and C. Camma A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma Hepatology 51 2010 1274 1283
15. J.M. Llovet, and J. Bruix Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 38 2003 429 442
16. J.F. Dufour, I. Bargellini, N. De Maria, P. De Simone, I. Goulis, and R.T. Marinho Intermediate hepatocellular carcinoma: current treatments and future perspectives Ann Oncol 24 2013 24 29
17. K. Takayasu, S. Arii, I. Ikai, M. Omata, K. Okita, and T. Ichida et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. The Liver Cancer Study Group of Japan Gastroenterology 131 2006 461 469
18. M. Burrel, M. Reig, A. Forner, M. Barrufet, C.R. de Lope, and S. Tremosini et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design J Hepatol 56 2012 1330 1335
19. J.M. Llovet, and J. Bruix Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 2008 1312 1327
20. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hildegard, E. Gane, and J.F. Blanc et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
21. S.M. Jung, J.W. Jang, C.R. You, S.H. Yoo, and J.H. Kwon et al. Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases J Gastroenterol Hepatol 27 2012 684 689
22. A. Vitale, R.R. Morales, G. Zanus, F. Farinati, P. Burra, and P. Angeli et al. Italian Liver Cancer Group. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study Lancet Oncol 12 2011 654 662
23. M.P. Bralet, J.M. Regimbeau, P. Pineau, S. Dubois, G. Loas, and F. Degos et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases Hepatology 32 2000 200 204
24. J. Lubrano, E. Huet, B. Tsilividis, A. François, O. Goria, and G. Riachi et al. Long-term outcome of liver resection for hepatocellular carcinoma in noncirrhotic nonfibrotic liver with no viral hepatitis or alcohol abuse World J Surg 32 2008 104 109
25. R.T. Poon, S.T. Fan, and J. Wong Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter J Am Coll Surg 194 2002 592 602
26. C.N. Yeh, W.C. Lee, and M.F. Chen Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung Memorial Hospital Ann Surg Oncol 10 2003 1070 1076
27. A.W. Hemming, A.I. Reed, R.J. Howard, S. Fujita, S.N. Hochwald, and J.G. Caridi et al. Preoperative portal vein embolization for extended hepatectomy Ann Surg 237 2003 686 691
28. M. Nagino, J. Kamiya, H. Nishio, T. Ebata, T. Arai, and Y. Nimura Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up Ann Surg 243 2006 364 372
29. W.T. Knoefel, I. Gabor, A. Rehders, A. Alexander, M. Krausch, and J. Schulte am Esch et al. In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two-stage liver resection Br J Surg 100 2013 388 394
30. A.A. Schnitzbauer, S.A. Lang, H. Goessmann, S. Nadalin, J. Baumgart, and S.A. Farkas et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings Ann Surg 255 2012 405 414
31. H. Lang, G.C. Sotiropoulos, E.I. Brokalaki, K.J. Schmitz, C. Bertona, and G. Meyer et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers J Am Coll Surg 205 2007 27 36
32. R.L. Smoot, D.M. Nagorney, and V.S. Chandan et al. Resection of hepatocellular carcinoma in patients without cirrhosis Br J Surg 98 2011 697 703
33. F. Cauchy, D. Fuks, and J. Belghiti HCC: current surgical treatment concepts Langenbecks Arch Surg 397 2012 681 695
34. I. Ikai, S. Arii, M. Kojiro, T. Ichida, M. Makuuchi, and Y. Matsuyama et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey Cancer 101 2004 796 802
35. E.G. Giannini, V. Savarino, F. Farinati, F. Ciccarese, G. Rapaccini, and M.D. Marco et al. Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients Liver Int 33 2013 1594 1600
36. J.H. Zhong, Y. Ke, W.F. Gong, B.D. Xiang, L. Ma, and X.P. Ye et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma Ann Surg 2013 [Epub ahead of print]
37. S. Raia, J.R. Nery, and S. Mies Liver transplantation from live donors Lancet 26 1989 497
38. V. Mazzaferro, E. Regalia, R. Doci, S. Andreola, A. Pulvirenti, and F. Bozzetti et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693 699
39. B. Ringe, R. Pichlmayr, C. Wittekind, and G. Tusch Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients World J Surg 15 1991 270 285
40. E.A. Pomfret, K. Washburn, C. Wald, M.A. Nalesnik, D. Douglas, and M. Russo et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States Liver Transpl 16 2010 262 278
41. J.P. Duffy, A. Vardanian, E. Benjamin, M. Watson, D.G. Farmer, and R.M. Ghobrial et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA Ann Surg 246 2007 502 511
42. P. Bhangui, E. Vibert, P. Majno, C. Salloum, P. Andreani, and J. Zocrato et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation Hepatology 53 2011 1570 1579
43. J.Y. Leung, A.X. Zhu, F.D. Gordon, D.S. Pratt, A. Mithoefer, and K. Garrigan et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study Liver Transpl 10 2004 1343 1354
44. C.H. Kwon, D.J. Kim, Y.S. Han, J.B. Park, G.S. Choi, and S.J. Kim et al. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis 25 2007 313 319
45. K. Vakili, J.J. Pomposelli, Y.L. Cheah, M. Akoad, W.D. Lewis, and U. Khettry et al. Living donor liver transplantation for hepatocellular carcinoma: increased recurrence but improved survival Liver Transpl 15 2009 1861 1866
46. B.A. Seinstra, O.M. van Delden, K.J. van Erpecum, R. van Hillegersberg, W.P. Mali, and van den Bosch Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: what is the evidence today Insights Imag 3 2010 167 181
47. R. Lencioni Loco-regional treatment of hepatocellular carcinoma Hepatology 52 2010 762 773
48. R. Lencioni, and L. Crocetti Local-regional treatment of hepatocellular carcinoma Radiology 262 2012 43 58
49. F. Brunello, A. Veltri, P. Carucci, E. Pagano, G. Ciccone, and P. Moretto et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial Scand J Gastroenterol 43 2008 727 735
50. R.A. Lencioni, H.P. Allgaier, D. Cioni, M. Olschewski, P. Deibert, and L. Crocetti et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection Radiology 228 2003 235 240
51. S.M. Lin, C.J. Lin, C.C. Lin, C.W. Hsu, and Y.C. Chen Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm Gastroenterology 127 2004 1714 1723
52. S.M. Lin, C.J. Lin, C.C. Lin, C.W. Hsu, and Y.C. Chen Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less Gut 54 2005 1151 1156
53. S. Shiina, T. Teratani, S. Obi, S. Sato, R. Tateishi, and T. Fujishima et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma Gastroenterology 129 2005 122 130
54. M.S. Chen, J.Q. Li, Y. Zheng, R.P. Guo, H.H. Liang, and Y.Q. Zhang et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma Ann Surg 243 2006 321 328
55. J. Huang, L. Yan, Z. Cheng, H. Wu, L. Du, and J. Wang et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria Ann Surg 252 2010 903 912
56. K. Feng, J. Yan, X. Li, F. Xia, K. Ma, and S. Wang et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma J Hepatol 57 2012 794 802
57. A. Cucchetti, F. Piscaglia, M. Cescon, G. Ercolani, and A.D. Pinna Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma World J Gastroenterol 19 2013 4106 4118
58. C. Duan, M. Liu, Z. Zhang, K. Ma, and P. Bie Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis World J Surg Oncol 11 2013 190
59. N. Ashoori, F. Bamberg, P. Paprottka, M. Rentsch, and F.T. Kolligs et al. Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation Digestion 86 2012 338 348
60. D.S. Lu, N.C. Yu, S.S. Raman, C. Lassman, M.J. Tong, and C. Britten et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation Hepatology 41 2005 1130 1137
61. F. Wu, Z.B. Wang, W.Z. Chen, H. Zhu, J. Bai, and J.Z. Zou et al. Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma Ann Surg Oncol 11 2004 1061 1069
62. C. Li, W. Zhang, R. Zhang, L. Zhang, P. Wu, and F. Zhang Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma Eur J Cancer 46 2010 2513 2521
63. M. Liao, J. Huang, T. Zhang, and H. Wu Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis PLOS One 8 2013 e68453
64. A.C. Chan, T.T. Cheung, S.T. Fan, K.S. Chok, S.C. Chan, and R.T. Poon et al. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma Ann Surg 257 2013 686 692
65. C.M. Pacella, G. Francica, F.M. DiLascio, V. Arienti, E. Antico, and B. Caspani et al. Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis J Clin Oncol 27 2009 2615 2621
66. V. Arienti, S. Pretolani, C.M. Pacella, F. Magnolfi, B. Caspani, and G. Francica et al. Complications of laser ablation for hepatocellular carcinoma: a multicenter study Radiology 246 2008 947 955
67. P. Liang, B. Dong, X. Yu, D. Yu, Y. Wang, and L. Feng et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation Radiology 235 2005 299 307
68. Y. Liu, Y. Zheng, S. Li, B. Li, Y. Zhang, and Y. Yuan Percutaneous microwave ablation of larger hepatocellular carcinoma Clin Radiol 68 2013 21 26
69. S. Ursino, C. Greco, F. Cartei, C. Colosimo, A. Stefanelli, and B. Cacopardo et al. Radiotherapy and hepatocellular carcinoma: update and review of literature Eur Rev Med Pharmacol Sci 16 2012 1599 1604
70. A. Bujold, C.A. Massey, J.J. Kim, J. Brierley, C. Cho, and R.K. Wong et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma J Clin Oncol 31 2013 1631 1639
71. Y. Honda, T. Kimura, H. Aikata, T. Kobayashi, T. Fukuhara, and K. Masaki et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma J Gastroenterol Hepatol 28 2013 530 536
72. A. Takeda, N. Sanuki, T. Eriguchi, T. Kobayashi, S. Iwabutchi, and K. Matsunaga et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma J Gastroenterol Hepatol 28 2013 530 536
73. J.K. O'Connor, J. Trotter, G.L. Davis, J. Dempster, G.B. Klintmalm, and R.M. Goldstein Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation Liver Transpl 18 2012 949 954
74. E. Liu, M.H. Stenmark, M.J. Schipper, J.M. Balter, M.L. Kessler, and E.M. Caoili et al. Stereotactic body radiation therapy for primary and metastatic liver tumors Transl Oncol 6 2013 442 446
75. C. Cammà, F. Schepis, A. Orlando, M. Albanese, L. Shahied, and F. Trevisani et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials Radiology 224 2002 47 54
76. D.Y. Lin, Y.F. Liaw, T.Y. Lee, and C.M. Lai Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma - a randomized controlled trial Gastroenterology 94 1988 453 456
77. Group d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire N Engl J Med 332 1995 1256 1261
78. G. Pelletier, M. Ducreux, F. Gay, M. Luboinski, H. Hagège, and T. Dao et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC J Hepatol 29 1998 129 134
79. J. Bruix, J.M. Llovet, A. Castells, X. Montañá, C. Brú, and M.C. Ayuso et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution Hepatology 27 1998 1578 1583
80. J.M. Llovet, M.I. Real, X. Montaña, R. Planas, S. Coll, and J. Aponte et al. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739
81. C.M. Lo, H. Ngan, W.K. Tso, C.L. Liu, C.M. Lam, and R.T. Poon et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
82. B.A. Radeleff, U. Stampfl, C.M. Sommer, N. Bellemann, K. Hoffmann, and T. Ganten et al. Transarterial ablation of hepatocellular carcinoma. Status and developments Radiologe 52 2012 44 55
83. J. Lammer, K. Malagari, T. Vogl, F. Pilleul, A. Denys, and A. Watkinson et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study Cardiovasc Intervent Radiol 33 2010 41 52
84. B. Guiu, F. Deschamps, S. Aho, F. Munck, C. Dromain, and V. Boige et al. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads J Hepatol 56 2012 609 617
85. G. Bonomo, V. Pedicini, L. Monfardini, P. Della Vigna, D. Poretti, and G. Orgera et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up Cardiovasc Intervent Radiol 33 2010 552 559
86. K. Malagari, M. Pomoni, A. Kelekis, A. Pomoni, S. Dourakis, and T. Spyridopoulos et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma Cardiovasc Intervent Radiol 33 2010 541 551
87. M.A. Morse, B.A. Hanks, P. Suhocki, P.L. Doan, E.A. Liu, and P. Frost et al. Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma Clin Colorectal Cancer 11 2012 185 190
88. J.L. Raoul, B. Sangro, A. Forner, V. Mazzaferro, F. Piscaglia, and L. Bolondi et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization Cancer Treat Rev 37 2011 212 220
89. G. Antoch, S.P. Mueller, M. Hamami, T.A. Heusner, J. Ertle, and P. Hilgard et al. Selective internal radiotherapy (SIRT) for hepatocellular carcinoma Rofo 182 2010 660 670
90. R. Salem, R.J. Lewandowski, L. Kulik, E. Wang, A. Riaz, and R.K. Ryu et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma Gastroenterology 140 2011 497 507
91. B. Sangro, L. Carpanese, R. Cianni, R. Golfieri, D. Gasparini, and S. Ezziddin et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation Hepatology 54 2011 868 878
92. P. Hilgard, M. Hamami, A.E. Fouly, A. Scherag, S. Müller, and J. Ertle et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival Hepatology 52 2010 1741 1749
93. A. Kennedy, S. Nag, R. Salem, R. Murthy, A.J. McEwan, and C. Nutting et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium Int J Radiat Oncol Biol Phys 68 2007 13 23
94. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
95. R. Lencioni, M. Kudo, S.L. Ye, J.P. Bronowicki, X.P. Chen, and L. Dagher et al. First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study Int J Clin Pract 66 2012 675 683
96. A. Hollebecque, S. Cattan, O. Romano, G. Sergent, A. Mourad, and A. Louvet et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score Aliment Pharmacol Ther 34 2011 1193 1201
97. J.E. Kim, B.Y. Ryoo, M.H. Ryu, H.M. Chang, D.J. Suh, and H.C. Lee et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function Cancer Chemother Pharmacol 68 2011 1285 1290
98. J.W. Park, Y.H. Koh, H.B. Kim, H.Y. Kim, S. An, and J.I. Choi et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma J Hepatol 56 2012 1336 1342
99. Y.H. Chung, G. Han, J.H. Yoon, J. Yang, J. Wang, and G.L. Shao et al. Interim analysis of START: study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial Int J Cancer 132 2013 2448 2458
100. A. Muhammad, M. Dhamija, G. Vidyarthi, D. Amodeo, W. Boyd, and B. Miladinovic et al. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma World J Hepatol 5 2013 364 371
101. R. Lencioni, J.M. Llovet, G. Han, W.Y. Tak, J. Jang, and M.A. Leberre et al. Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial 2012 ASCO LBA154
102. R.S. Finn Emerging targeted strategies in advanced hepatocellular carcinoma Semin Liver Dis 33 2013 S11 S19
103. S.L. Chan, T. Mok, and B.B.Y. Ma Management of hepatocellular carcinoma: beyond sorafenib Curr Oncol Rep 14 2012 257 266
104. J. Dekervel, J. van Pelt, and C. Verslype Advanced unresectable hepatocellular carcinoma: new biologics as fresh ammunition or clues to disease understanding? Curr Opin Oncol 25 2013 409 416
105. A. Santoro, L. Rimassa, I. Borbath, B. Daniele, S. Salvagni, and J.L. Van Laethem et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study Lancet Oncol 14 2013 55 63